Suchergebnisse - "Buka, Richard J"

PubPharm (26)

1

Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate

enthalten in: Journal of thrombosis and thrombolysis | 2024

von Buka, R. | Sutton, D. | Nicolson, P.

2

Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate

enthalten in: Journal of thrombosis and thrombolysis | 2024

von Buka, R. | Sutton, D. | Nicolson, P.

3

PF4 activates the c-Mpl-Jak2 pathway in platelets

enthalten in: Blood | 2024

von Buka, R. | Montague, S. | Moran, L. | +4

CommentIn: Blood. 2024 Jan 4;143(1):7-9. - PMID 38175681

4

Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2, and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand

enthalten in: Journal of thrombosis and haemostasis : JTH | 2024

von Martin, E. | Clark, J. | Montague, S. | +10

5

Blood Coagulation and Beyond : Position Paper from the Fourth Maastricht Consensus Conference on Thrombosis

enthalten in: Thrombosis and haemostasis | 2023

von Akbulut, A. | Arisz, R. | Baaten, C. | +61

6

UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease

enthalten in: EJHaem | 2023

von Buka, R. | Roy, N. | Nicolson, P.

7

How will UK hospitals use andexanet alfa? A review of local protocols

enthalten in: EJHaem | 2023

von Glancy, P. | Sutton, D. | Gomez, K. | +2

8

DOACs for VTE in patients with brain cancer and brain metastases : choices, choices, choices

enthalten in: Blood advances | 2023

von Buka, R. | Sutton, D.

CommentOn: Blood Adv. 2022 Aug 23;6(16):4873-4883. - PMID 35772127

9

UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease

enthalten in: eJHaem | 2023

von Buka, R. | Roy, N. | Nicolson, P.

10

Heterozygous, germline JAK2 E846D substitution as the cause of familial erythrocytosis

enthalten in: British journal of haematology | 2022

von Tun, P. | Buka, R. | Graham, J. | +1